ABX464 is an investigational drug.
There have been 19 clinical trials for ABX464.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2022.
The most common disease conditions in clinical trials are Colitis, Ulcerative, Colitis, and Ulcer. The leading clinical trial sponsors are Abivax S.A., FLS-RS, and Orion Corporation, Orion Pharma.
There are thirty US patents protecting this investigational drug and six hundred and two international patents.